ArticleNanoscale2012
Development of viral nanoparticles for efficient intracellular delivery.
Article in Nanoscale, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 60 citations in OpenAlex.
- Cellular fate of a plant virus immunotherapy candidate.Communications biology · 2024Article
- Preparation and Catalytic Properties of Carbonic Anhydrase Conjugated to Liposomes through a Bis-Aryl Hydrazone Bond.ACS omega · 2023Article
- Genetically Engineered Viral Vectors and Organic-Based Non-Viral Nanocarriers for Drug Delivery Applications.Advanced healthcare materials · 2022Review
- Recent progress in targeted delivery vectors based on biomimetic nanoparticles.Signal transduction and targeted therapy · 2021Review
- The Immunogenicity of Capsid-Like Particle Vaccines in Combination with Different Adjuvants Using Different Routes of Administration.Vaccines · 2021Article
- The Utilization of Cell-Penetrating Peptides in the Intracellular Delivery of Viral Nanoparticles.Materials (Basel, Switzerland) · 2019Review
- Plant/Bacterial Virus-Based Drug Discovery, Drug Delivery, and Therapeutics.Pharmaceutics · 2019Review
- VLPs Derived from the CCMV Plant Virus Can Directly Transfect and Deliver Heterologous Genes for Translation into Mammalian Cells.BioMed research international · 2019Article
- Biomimetic Nanoparticle Vaccines for Cancer Therapy.Advanced biosystems · 2019Article
- Delivery of mitoxantrone using a plant virus-based nanoparticle for the treatment of glioblastomas.Journal of materials chemistry. B · 2018Article
- Different-Length Hydrazone Activated Polymers for Plasmid DNA Condensation and Cellular Transfection.Biomacromolecules · 2018Article
- Virus-like particles: Next-generation nanoparticles for targeted therapeutic delivery.Bioengineering & translational medicine · 2017Review
- Design of virus-based nanomaterials for medicine, biotechnology, and energy.Chemical Society reviews · 2016Review
- Utilizing Viral Nanoparticle/Dendron Hybrid Conjugates in Photodynamic Therapy for Dual Delivery to Macrophages and Cancer Cells.Bioconjugate chemistry · 2016Article
- Article
- Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies.Breast cancer : basic and clinical research · 2015Review
- Active targeted drug delivery for microbes using nano-carriers.Current topics in medicinal chemistry · 2015Review
- Viral nanoparticle-encapsidated enzyme and restructured DNA for cell delivery and gene expression.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Biodistribution, pharmacokinetics, and blood compatibility of native and PEGylated tobacco mosaic virus nano-rods and -spheres in mice.Virology · 2014Article
- Genetic engineering and chemical conjugation of potato virus X.Methods in molecular biology (Clifton, N.J.) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Viral nanoparticles (VNPs) based on plant viruses such as Cowpea mosaic virus (CPMV) can be used for a broad range of biomedical applications because they present a robust scaffold that allows functionalization by chemical conjugation and genetic modification, thereby offering an efficient drug delivery platform that can target specific cells and tissues. VNPs such as CPMV show natural affinity to cells; however, cellular uptake is inefficient. Here we show that chemical modification of the CPMV surface with a highly reactive, specific and UV-traceable hydrazone linker allows bioconjugation of polyarginine (R5) cell penetrating peptides (CPPs), which can overcome these limitations. The resulting CPMV-R5 particles were taken up into a human cervical cancer cell line (HeLa) more efficiently than native particles. Uptake efficiency was dependent on the density of R5 peptides on the surface of the VNP; particles displaying 40 R5 peptides per CPMV (denoted as CPMV-R5H) interact strongly with the plasma membrane and are taken up into the cells via an energy-dependent mechanism whereas particles displaying 10 R5 peptides per CPMV (CPMV-R5L) are only slowly taken up. The fate of CPMV-R5 versus native CPMV particles within cells was evaluated in a co-localization time course study. It was indicated that the intracellular localization of CPMV-R5 and CPMV differs; CPMV remains trapped in Lamp-1 positive endolysosomes over long time frames; in contrast, 30-50% of the CPMV-R5 particles transitioned from the endosome into other cellular vesicles or compartments. Our data provide the groundwork for the development of efficient drug delivery formulations based on CPMV-R5.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.